Activities Report and Appendix 4C for June 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June 2021.
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography (PET).
Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
Telix is delighted to announce the appointment of Gabrielle Wermenbol as Chief Financial Officer, Europe, Middle East and Africa (EMEA).
Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations
Telix is pleased to announce that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor Relations.
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder cancer.
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line therapy.
Telix Update on FDA New Drug Application Review for Illuccix®
Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product Illuccix®.
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
Telix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied Radiology.
Scott Law joins Telix as SVP Global Manufacturing Operations
Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing Operations.
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA Association.